Reuters logo
BRIEF-Synthetic Biologics says confirms key features of Phase 2B/3 trial of SYN-010
January 18, 2017 / 10:04 PM / 8 months ago

BRIEF-Synthetic Biologics says confirms key features of Phase 2B/3 trial of SYN-010

Jan 18 (Reuters) - Synthetic Biologics Inc

* Synthetic Biologics confirms key features of pivotal Phase 2b/3 trial of SYN-010 pursuant to consultations with FDA

* Synthetic Biologics confirms key features of pivotal phase 2B/3 trial of SYN-010 pursuant to consultations with FDA

* Synthetic Biologics Inc says company anticipates initiating this trial by end of Q1 of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below